These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1251 related items for PubMed ID: 29241762

  • 1. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong RSM, Anagnostopoulos A, Brenner B, Denzlinger C, Rossi G, Nagler A, Garcia-Delgado R, Portella MSO, Zhu Z, Selleslag D.
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [Abstract] [Full Text] [Related]

  • 2. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK.
    Lancet; 2015 Oct 24; 386(10004):1649-58. PubMed ID: 26231455
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H, Kreuzer KA, Monsef I, Skoetz N.
    Cochrane Database Syst Rev; 2017 Sep 30; 9(9):CD009883. PubMed ID: 28962071
    [Abstract] [Full Text] [Related]

  • 7. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study.
    Frey N, Jang JH, Szer J, Illés Á, Kim HJ, Ram R, Chong BH, Rowe JM, Borisenkova E, Liesveld J, Winer ES, Cherfi A, Aslanis V, Ghaznawi F, Strickland S.
    Lancet Haematol; 2019 Mar 30; 6(3):e122-e131. PubMed ID: 30704923
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB.
    Lancet; 2011 Jan 29; 377(9763):393-402. PubMed ID: 20739054
    [Abstract] [Full Text] [Related]

  • 11. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
    Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A.
    Lancet Haematol; 2018 Mar 29; 5(3):e117-e126. PubMed ID: 29396092
    [Abstract] [Full Text] [Related]

  • 12. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.
    Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella MSO, Burgess P, Ramos PM, Choi J, Platzbecker U, SUPPORT study investigators.
    Blood; 2018 Dec 20; 132(25):2629-2638. PubMed ID: 30305280
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D, ELEVATE Study Group.
    N Engl J Med; 2012 Aug 23; 367(8):716-24. PubMed ID: 22913681
    [Abstract] [Full Text] [Related]

  • 15. Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study.
    Mittelman M, Platzbecker U, Grosicki S, Lawniczek T, Zhu Z, Selleslag D.
    Acta Haematol; 2023 Aug 23; 146(5):373-378. PubMed ID: 37231838
    [Abstract] [Full Text] [Related]

  • 16. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D.
    Gastroenterology; 2014 Feb 23; 146(2):442-52.e1. PubMed ID: 24126097
    [Abstract] [Full Text] [Related]

  • 17. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
    Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A, Patriarca A, Crisà E, Capodanno I, Salutari P, Reda G, Cascavilla N, Ferrero D, Guarini A, Tripepi G, Iannì G, Russo E, Castelli A, Fattizzo B, Beltrami G, Bocchia M, Molteni A, Fenaux P, Germing U, Ricco A, Palumbo GA, Impera S, Di Renzo N, Rivellini F, Buccisano F, Stamatoullas-Bastard A, Liberati AM, Candoni A, Delfino IM, Arcadi MT, Cufari P, Rizzo L, Bova I, D'Errigo MG, Zini G, Latagliata R.
    J Clin Oncol; 2023 Oct 01; 41(28):4486-4496. PubMed ID: 37294914
    [Abstract] [Full Text] [Related]

  • 18. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
    McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH, TPL102357 Study Group.
    N Engl J Med; 2007 Nov 29; 357(22):2227-36. PubMed ID: 18046027
    [Abstract] [Full Text] [Related]

  • 19. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
    Desborough M, Hadjinicolaou AV, Chaimani A, Trivella M, Vyas P, Doree C, Hopewell S, Stanworth SJ, Estcourt LJ.
    Cochrane Database Syst Rev; 2016 Oct 31; 10(10):CD012055. PubMed ID: 27797129
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.
    Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, Patwardhan R, Messam C, Mostafa Kamel Y.
    Curr Med Res Opin; 2010 Oct 31; 26(10):2339-46. PubMed ID: 20735290
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.